As a result of petitions from advocacy groups such as the Lupus Research Institute and Lupus UK, patients in Great Britain may be able to take the newest lupus treatment Benlysta (belimumab)with national healthcare coverage. This past spring, Great Britain’s National Institute for Health and Clinical Excellence (NICE) had turned down the use of Benlysta on the National Health Service for patients lupus, claiming that its benefit was not enough to justify its cost. This is a very encouraging development for lupus patients in Great Britain as well as those throughout the world. The Lupus Research Institute is proud to have helped to effectively urge NICE to appreciate the critical need for treatment among people with lupus.
Please continue to amplify our voice so NICE hears the need loud and clear by joining petitioners from around the world at http://www.thepetitionsite.com/1/cover-Benlysta/.